Tranexamic Acid for Intracerebral Hemorrhage in Patients on Non-Vitamin K Antagonist Oral Anticoagulants (TICH-NOAC): A Multicenter, Randomized, Placebo-Controlled, Phase 2 Trial.

"Disclosures Dr Polymeris: funding from Swiss Academy of Medical Sciences (SAMS)/Bangerter-Rhyner-Foundation, Swiss Heart Foundation (SHF). Dr Siepen: funding from SAMS/Bangerter-Rhyner-Foundation. Dr Tsakiris: unrestricted research grants and lecture honoraria from Bayer Schweiz AG, Pfizer, Daiichi Sankyo, Takeda. Dr Sprigg: grants from the National Institute of Health Research. Dr Thilemann: travel grants from Bristol Myers Squibb (BMS)/Pfizer. Dr Wagner: funding by the Doc.Mobility instrument of the Swiss National Science Foundation (SNSF), Prof Dr med Karl und Rena Theiler-Haag Stiftung. Dr Traenka: research grants from SHF; personal research scholarships from the Novartis Foundation for biological and medical research, Freiwillige Akademische Gesellschaft Basel, Bangerter-Rhyner Foundation, and University of Basel; travel grants from Bayer. Dr Gensicke: research support from SNSF; advisory board honoraria from Daiichi Sankyo; funding for travel from BMS/Pfizer, and AbbVie. Dr De Marchis: support from SNSF (Nr.32003B_200573 and Nr.PBBEP3_139388); Spezialprogramm Nachwuchsförderung Klinische Forschung, University of Basel; Science Funds (Wissenschaftspool) of the University Hospital Basel; SHF; ProPatient Foundation Basel; Bangerter-Rhyner-Stiftung; Swisslife Jubiläumsstiftung for Medical Research; Swiss Neurological Society; Fondazione Dr. Ettore Balli; DeQuervain research grant; Thermo Fisher GmbH; Novartis grant; travel honoraria from Bayer, BMS/Pfizer; speaker honoraria from Bayer, Medtronic; consultant honoraria from Bayer, Novartis; member of the Steering Committee of PACIFIC Stroke (https://clinicaltrials.gov; NCT04304508); Industry payments made to the research fund of the University Hospital Basel. Dr Bonati: compensation from BMS for consultant services; compensation from Amgen for consultant services; grants from SHF; grants from Stiftung zur Förderung der gastroenterologischen und allgemeinen klinischen Forschung sowie der medizinischen Bildauswertung; travel support from Bayer; grants from University of Basel; grants from SNSF; grants from AstraZeneca; compensation from AstraZeneca for consultant services; travel support from AstraZeneca; compensation from Bayer for consultant services; and compensation from Claret Medical, Inc, for data and safety monitoring services. Dr Fischer: financial support for the SWIFT DIRECT trial from Medtronic; research grants from Medtronic BEYOND SWIFT registry, SNSF, SHF; compensation from Biogen and Boehringer Ingelheim for expert witness services and consulting fees from Medtronic, Stryker, CSL Behring (fees paid to the institution); membership of a Data Safety Monitoring Board for the IN EXTREMIS trial, TITAN trial; Portola (Alexion) Advisory board (fees paid to the institution); compensation from Phenox, Inc, for end point review committee services; grants from Phenox, Inc, Rapid Medical, Penumbra; Vice Presidency of the Swiss Neurological Society. Dr Wegener: research funds by SNSF, UZH Clinical Research Priority Program stroke, Zurich Neuroscience Center, Baugarten Foundation; speaker honoraria from Amgen, Springer, Teva Pharma; consultancy fee from Bayer, Novartis. Dr Baumgartner: research funds from SAMS/Bangerter-Rhyner-Foundation; funding for travel and conference fees from BMS/Pfizer. Dr Engelter: funding for travel or speaker honoraria from Bayer, Boehringer Ingelheim, Daiichi Sankyo; scientific advisory boards for Bayer, Boehringer Ingelheim, BMS/Pfizer, MindMaze; editorial board of Stroke; research funding to his institutions from Pfizer (educational grant), Stago (compensation for educational efforts), Daiichi Sankyo, Science Funds (Wissenschaftsfonds) University Hospital Basel, University of Basel, Wissenschaftsfonds Rehabilitation University Department for Geriatric Medicine Felix Platter, Freiwillige Akademische Gesellschaft Basel, SHF, SNSF. Dr Seiffge: research support from Science Funds and Stroke Funds University Hospital Basel, SNSF, Swiss Society of Neurology, Bangerter-Rhyner-Foundation, Daiichi Sankyo, Stago (compensation for educational efforts); thrombosis research prize from Bayer Foundation; advisory boards and consultancy for Portola/Alexion/AstraZeneca, Bayer, VarmX. Dr Peters: research support from SHF, SNSF; speaker honoraria from Vifor Pharma, OM Pharma; scientific advisory boards for Daiichi Sankyo, AstraZeneca, OM Pharma; compensation from Medtronic, Novo Nordisk, Vifor Pharma for expert witness services; compensation from Boehringer Ingelheim, AstraZeneca, Novo Nordisk for other services. Dr Lyrer: research support from SNSF, SHF, Research Funds Neurology University Hospital Basel; advisory boards for Boehringer Ingelheim, Bayer, Recordati SA, Daiichi Sankyo; travel support from Pfizer; compensation from Biogen for other services; compensation from Pfizer, Boehringer Ingelheim for consultant services. The other authors report no conflicts."

"Sources of Funding TICH-NOAC (Treatment of Intracerebral Hemorrhage in Patients on Non–Vitamin K Antagonist Oral Anticoagulants With Tranexamic Acid) was funded by the Swiss National Science Foundation (grant number 32003B_163378), the Stroke Fund, Neurology Fund, and Scientific Fund of the University Hospital Basel. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report."

"The trial was overseen by a Steering Committee and run by an Executive Committee based at the University Hospital Basel and chaired by P.A.L. An independent data safety monitoring board was planned but was not appointed due to early trial termination. The trial was prospectively registered at https://clinicaltrials.gov (August 15, 2016; NCT02866838) before enrolling the first patient. REGISTRATION:: URL: https://clinicaltrials.gov; Unique identifier: NCT02866838."